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Approximately one-third of aneurysmal subarachnoid hemorrhage (aSAH) patients
develop delayed cerebral vasospasm (DCV) 3–10 days after aneurysm rupture resulting
in additional, permanent neurologic disability. Currently, no validated biomarker is
available to determine the risk of DCV in aSAH patients. MicroRNAs (miRNAs) have been
implicated in virtually all human diseases, including aSAH, and are found in extracellular
biofluids including plasma and cerebrospinal fluid (CSF). We used a custom designed
TaqMan Low Density Array miRNA panel to examine the levels of 47 selected brain
and vasculature injury related miRNAs in CSF and plasma specimens collected from
31 patients with or without DCV at 3 and 7 days after aSAH, as well as from eight
healthy controls. The analysis of the first 18-patient cohort revealed a striking differential
expression pattern of the selected miRNAs in CSF and plasma of aSAH patients with
DCV from those without DCV. Importantly, this differential expression was observed at
the early time point (3 days after aSAH), before DCV event occurs. Seven miRNAs
were identified as reliable DCV risk predictors along with a prediction model constructed
based on an array of additional 19 miRNAs on the panel. These chosen miRNAs were
then used to predict the risk of DCV in a separate, testing cohort of 15 patients.
The accuracy of DCV risk prediction in the testing cohort reached 87%. The study
demonstrates that our novel designed miRNA panel is an effective predictor of DCV
risk and has strong applications in clinical management of aSAH patients.
Keywords: microRNA, biomarker, aneurysmal subarachnoid hemorrhage, delayed cerebral vasospasm,
cerebrospinal fluid, plasma

INTRODUCTION
Aneurysmal subarachnoid hemorrhage (aSAH) is a catastrophic event that occurs when an
intracranial arterial aneurysm ruptures, resulting in the release of oxygenated blood into the
subarachnoid space (Dority and Oldham, 2016). Delayed cerebral vasospasm (DCV) has long
been considered the most devastating acute complication following aSAH (Janjua and Mayer, 2003;
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Score > 3 (Frontera et al., 2006), and a ventriculostomy
(EVD: external ventricular drain) being placed prior to postbleed-day 3 (PBD3). Patients were excluded if they arrived
at the hospital in a non-survivable condition or were likely
to die prior to PBD14 as determined by the attending
physicians. Patients also were excluded if they had a history
of systemic inflammatory disease or chronically dosed with
a biologic inflammatory modulator. Finally, patients were
excluded if a legally authorized representative (LAR) could
not be located by PBD3 or who refused (or their LAR
refused) consent.
During hospitalization, all patients were treated according
to local standard of care. Patients were considered to have
DCV if, during their hospitalization, the daily transcranial
Doppler (TCD) monitoring demonstrated a mean flow
velocity > 120 cm/sec in either middle cerebral artery (MCA)
and a calculated Lindegaard ratio >3.0 (Kirsch et al., 2013).

Al-Mufti et al., 2017; Brami et al., 2020). Approximately 30% of
aSAH patients develop DCV (Janjua and Mayer, 2003), which
commonly occurs during 3–10 days after aneurysm rupture,
requiring frequent neurologic monitoring and rapid, intensive
interventions to minimize further injury and disability. The
pathological events contributing to DCV are poorly understood
but appear to include calcium dependent and independent
vasoconstriction, oxidative stress, endothelial dysfunction,
inflammatory responses, apoptosis, autophagy, and altered gene
expression (Macdonald and Weir, 1991; Dietrich and Dacey,
2000; Kolias et al., 2009; Carr et al., 2013; Eisenhut, 2014;
Miller et al., 2014; Chou, 2018). Predicting DCV risk before it
becomes clinically symptomatic is crucial to limiting further
injury. Unfortunately, no effective biomarker exists to predict
DCV at a time point when neurologic injury can be prevented
(Mocco et al., 2006; Etminan et al., 2011). At this time, clinical
management includes a “wait and see” approach. Therefore,
there is an urgent need to identify biomarkers that determine
DCV risk/susceptibility in order to implement preventive or
management strategies.
MicroRNAs (miRNAs) are small, non-coding, regulatory
RNAs (Bartel, 2004; Huntzinger and Izaurralde, 2011). MiRNAs
regulate all aspects of cellular function, and disruption of miRNA
activity contributes to many disease states including neurological
diseases such as Alzheimer’s disease, stroke, and traumatic brain
injury (Wang et al., 2008, 2010, 2015; Liu and Xu, 2011; Tan
et al., 2011; Koutsis et al., 2013; Hill and Lukiw, 2016). Several
studies have demonstrated changes in miRNA levels in cerebral
arteries following aSAH and DCV (Vikman et al., 2006; Muller
et al., 2015; Li et al., 2018). For example, over 150 miRNAs were
differentially expressed in the aneurysmal tissue when compared
to normal arteries (Liu et al., 2014). MiRNAs are also recognized
as powerful regulators of CNS inflammatory responses (O’connell
et al., 2012), including that occurs following stroke and aSAH
(Khoshnam et al., 2017; Lopes et al., 2018). Their functional
role and the fact that miRNA can be secreted into extracellular
fluids make them attractive candidates as biomarkers. Moreover,
miRNAs in biofluids are highly stable at room temperature,
resistant to RNase activity (Mraz et al., 2009) and relatively
easy to detect and quantify (Etheridge et al., 2011). In this
study, we explore the potential of using cerebral spinal fluid
(CSF) and plasma miRNAs as biomarkers to predict DCV events
in aSAH patients.

Cell-Free CSF and Plasma Sample
Collection
After written consent was obtained, CSF and plasma were
collected at PBD 3, 5, 7, and 10 using a standard protocol. CSF
was collected directly from the EVD drainage tubing. Collected
samples were centrifuged at 3,000 × g for 5 min and the
supernatant aliquoted into 250-µl aliquots and frozen at -80 C
until further analysis. The miRNA analysis was performed only
from the specimens collected at PBD3 and PBD7.
In addition, frozen plasma and CSF samples from several deidentified cases were gifted from the University of Pennsylvania
(UPENN). This data set and biofluids had already been collected
and no information on data collection or sample preparation
were available. Therefore, they only were used in testing
prediction model.
Finally, CSF and plasma specimens from eight healthy persons
who had no clinically manifest neurological disease/diagnosis
were procured from the University of Kentucky Alzheimer’s
Disease Center (UK-ADC) biobank.

Experimental Design
A total of 39 patients and controls were analyzed in three
separated groups according to the availability of the specimens
at the time of analysis (Figure 1). Group A was analyzed in
June 2019 and included eighteen aSAH patients (10 DCV-, 8
DCV+) from UKCMC and 8 healthy controls (HCs). Group B
was analyzed in September 2019 and included nine aSAH patients
including two experimental duplicates from Group A, three
additional cases from UKCMC, and four cases from UPENN.
Group C was analyzed in January 2020 and included six aSAH
patients from UKCMC. The data from Group A was used as
a training set to build a risk prediction model for testing the
discrimination ability of the miRNA panel in Group B and Group
C. Differences in demographics and clinical observations were
evaluated using Fisher’s exact test.
A blinding procedure was implemented in this project. The
physicians who diagnosed and treated the patient, and those
that collected and aliquoted the specimens did not perform

MATERIALS AND METHODS
Patient Cohorts
All procedures and protocols related to the human participants
and collections of specimens were approved by the University
of Kentucky Institutional Review Board (IRB) that are in
compliance with the 1964 Helsinki declaration and its later
amendments. Following the approved IRB protocol (# 55914),
all patients admitted to the University of Kentucky Chandler
Medical Center (UKCMC) were screened for inclusion in this
study. Inclusion criteria included being 18 years of age or
older, radiographically evidence of aSAH, a Modified Fischer
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FIGURE 1 | Flowchart of patient groups and sample analysis. DCV: delayed cerebral vasospasm.

the miRNA analysis. Likewise, miRNA analyses were performed
by personnel blinded to patient data and clinical outcome.
Clinical and laboratory data were only unblinded after all data
were acquired. The statisticians who constructed the prediction
models were not involved in either the sample collection
or miRNA analysis.

TLDA Data Processing
Quantitative real-time PCR run files were imported to and
analyzed using Thermo Fisher Cloud Software—Relative
Quantification. The relative threshold cycle (Crt ) method
(Applied Biosystems, 2016) was applied to acquire the
quantitative Crt values from all runs in each experiment.
Crt values that failed software-defined QC and/or values equal to
or more than 35 were considered as undetectable and excluded
from further analysis. Furthermore, a miRNA would be removed
from analysis if it was not detected in one third of tested samples.
The TLDA consisted of specific selected miRNAs and an internal
normalizer could not be identified. Therefore, the Global Mean
Normalization method (Mestdagh et al., 2009) was used to
normalize the TLDA data. Raw Crt values and the geometric
mean of a given sample was used to obtain 1Crt values calculated
as 1Crt = Crt−target - Crt−geomean for each miRNA. The time for
processing 2–8 samples from RNA isolation to data analysis is
around 6–8 h (Supplementary Figure 1).

Design of a Customized Brain and
Vasculature Injury Related miRNA Panel
A customized panel containing miRNAs associated with brain
and vasculature injury was designed as described previously
(Wang et al., 2017) and used to generate a TaqMan miRNA
RT-qPCR low density array (TLDA, Thermo Fisher Scientific,
Waltham, MA, United States) that can simultaneously analyze 48
miRNAs in 8 independent samples.
R

RNA Isolation From CSF and Plasma
CSF and plasma total RNA were isolated using miRNeasy
Serum/Plasma Advanced Kit (Cat #: 217204, Qiagen, Hilden,
Germany) following manufacturer’s protocol. RNA was eluted
with 30 µl of nuclease-free water containing 0.5 U/µl
RNAsin (RNase inhibitor, Cat #: N2115, Promega, Madison,
WI, United States).

RT-qPCR Using Customized TaqMan
Low-Density Array (TLDA)

Statistical Analysis
GraphPad Prism 8.0.2 (San Diego, CA, United States) and R
(version 4.0.2) (R Core Team, 2020) were used for statistical
analyses. Student’s t-tests (2-tailed) were used to evaluate mean
differences for individual miRNAs. A 95% confidence interval
with p < 0.05 being considered statistically significant. The
receiver operating characteristics (ROC) were generated to
evaluate DCV discrimination ability of individual miRNAs.

R

MiRNA reverse transcription and real-time PCR detection
procedures were performed following the manufacturer’s
instruction and are also described in detail in prior publications
(Wang et al., 2014, 2017).
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A DCV prediction model was constructed using the Group A
CSF/PBD3 dataset. The model used the 26 miRNAs (“variables,”
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Supplementary File 1) that did not have any missing data
across all 3 patient groups. Among the 26 miRNAs, the
expression levels of 7 miRNAs exhibited perfect discrimination
between DCV+ and DCV- patient groups in the Group A
dataset (Supplementary Figure 2 and Supplementary File 1).
These seven miRNAs each served as individual predictors
in a consensus predictive tool. The remaining 19 miRNAs
were used to generate a decision tree using the Recursive
partitioning and regression trees (Therneau and Atkinson, 2019)
(Rpart) algorithm in R.

Design and Performance of the
Customized Brain and Vasculature Injury
Related miRNA Panel
We developed a customized miRNA panel consisting of 47
miRNAs relevant to brain and vasculature injury events (Table 2).
MiRNAs that met any of following criteria were selected: (1)
strong association with CNS injury or cerebrovascular damage,
either identified in our prior studies (Wang et al., 2015, 2017) or
reported in the literature; (2) implication in previous biomarker
studies related to CNS injury (TBI, SCI, or neurodegeneration)
or stroke; (3) potential data normalizer; (4) is detectable in CSF
and plasma. The panel contained one additional rodent specific
miRNA and the manufacturer’s mandatory control U6, both of
which were excluded from analysis. CSF and plasma miRNA
from a total of 31 aSAH patients (27 patients from UKCMC
and 4 from UPENN) and 8 HCs were included in the TLDA
analysis (Figure 1).
A miRNA was deemed detectable if it exhibited a Crt < 35 in at
least two-thirds of the total specimens. Based on these criteria, six
miRNAs from the CSF samples (miR-107, miR-144-3p, miR-1533p, miR-15a-5p, miR-29b-3p, and miR-874-3p) and six miRNAs
from the plasma samples (miR-124-3p, miR-144-3p, miR-12985p, miR-153-3p, miR-874-3p, and miR-9-5p) were removed from
further analysis. Overall, a clear and distinct miRNA expression
pattern was observed between the DCV+ and DCV- groups,
aSAH and HC groups, and between sampling times (PBD3 vs.
PBD7) in both biofluids (Figure 2).

RESULTS
Demographic and Pathological Data of
Study Cohorts
From July 2018 to December 2019, 77 patients were admitted
to UKCMC with aSAH, of these, 27 were included in this
study. There were no significant differences between the patients
with DCV (DCV+) and patients without DCV (DCV-) based
on age, gender, height, weight, body mass index, ethnic origin
(Table 1). Furthermore, no significant differences were observed
between the two study groups in the classification of the severity
of subarachnoid hemorrhage (Hunt Hess score, WFNS score,
and modified Fischer score), location of the aneurysm, or the
type of aneurysm obliteration. The average age of the HC
group was older than that of aSAH patients, however, we were
primarily interested in the comparison between DCV+ and
DCV- patients and the HC group served as a secondary
reference. Therefore, the age difference was not considered a
confounding factor.

Individual miRNA Performance in CSF
and Plasma
The majority of the selected miRNAs in CSF and plasma showed
significant differential expression between DCV+ and DCVat PBD3, but was reduced by PBD7 (Table 3). The difference
was especially robust in CSF specimens obtained at PBD3.
Specifically, 37 miRNAs from the CSF demonstrated highly
significant differences in samples collected from DCV+ relative
to DCV- patients at PBD3. Several miRNAs including Let-7b-5p,
miR-15b-5p, miR-17-5p, miR-19b-3p, miR-20a-5p, miR-24-3p,
and miR-29a-3p exhibited remarkable differential levels between
the DCV+ and DCV- groups at PBD3, as well as between the
DCV+/PBD3 group and HCs (Figure 3 and Supplementary
Figure 2). With respect to the plasma specimens, 29 miRNAs
demonstrated significant differential expression between the
DCV+ and DCV- groups at PBD3 (Table 3), with several
miRNAs (Let-7a-5p, miR-146a-5p, miR-204-5p, miR-221-3p,
miR-23a-3p, miR-497-5p) showing high differential expression
patterns (Figure 4).

TABLE 1 | Demographic and statistics of the study population.
Healthy
control
N=8

DCV
N = 12

Age (years)

74.3 ± 7.0 59.3 ± 18.2

Gender (male)

3 (37.5%)

Height (cm)

3 (25.0%)

No DCV
N = 17

p-value
(DCV vs.
No DCV)

59.4 ± 12.3

0.99

9 (52.9%)

0.25

N.D.

166.9 ± 11.6 171.8 ± 10.1

0.24

Weight (kg)

N.D.

97.1 ± 27.4

92.7 ± 26.8

0.67

Body mass index (kg/m2 )

N.D.

34.6 ± 7.7

30.9 ± 6.6

0.18

8 (100%)

11 (91.7%)

15 (88.2%)

1.00

Hunt Hess score (3–5)

N/A

8 (66.7%)

10 (58.8%)

0.72

WFNS score (3–5)

N/A

6 (50.0%)

5 (29.4%)

0.44

Modified Fischer score (4)

N/A

6 (50.0%)

7 (41.1%)

0.71

Aneurysm located (yes)

N/A

12 (100%)

13 (76.5%)

0.12

Aneurysm location (anterior)

N/A

7 (58.3%)

7 (53.9%)

0.46

Aneurysm obliteration type
(coiled)

N/A

11 (91.7%)

13 (100%)

0.37

Ethnic origin
(White/Caucasian)

Receiver Operating Characteristic (ROC)
Curves of Individual miRNAs
The sensitivity and specificity of individual miRNAs as predictors
of DCV were examined using the area under the ROC curve
(AUC). Many miRNAs demonstrated an AUC greater than 0.9 in
CSF collected at PBD3 indicating a highly significant predictive
ability of these miRNAs (Figure 5A). Of note, the AUC of
Let-7b-5p, miR-15b-5p, miR-17-5p, miR-19b-3p, miR-20a-5p,

Baseline demographics of aneurysmal subarachnoid hemorrhage (aSAH) patients
from UKCMC grouped based on whether or not they developed delayed cerebral
vasospasm (DCV) during hospitalization. Continuous variables are described as
mean ± SD with differences evaluated by an unpaired t-test. Categorical variables
are described as N and% with differences evaluated by Fisher’s exact test. N.D.,
no data available; N/A, not applicable.
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TABLE 2 | Selection of brain- and vasculature injury related miRNAs.
Assay ID

miRNAa

Sequence

Relevance to aSAH and cerebral vasculature

000377

hsa-let-7a-5pb

UGAGGUAGUAGGUUGUAUAGUU

Inflammatory/immune response

002619

hsa-let-7b-5pb

UGAGGUAGUAGGUUGUGUGGUU

Angiogenesis/inflammatory and immune response

000379

hsa-let-7c-5pb

UGAGGUAGUAGGUUGUAUGGUU

Inflammatory/immune response

000439

hsa-miR-103a-3pb

AGCAGCAUUGUACAGGGCUAUGA

Cell migration/wound healing

000443

hsa-miR-107b

AGCAGCAUUGUACAGGGCUAUCA

Inflammatory response/cell migration/wound healing

000449

hsa-miR-125b-5pb

UCCCUGAGACCCUAACUUGUGA

Cell proliferation/neuronal Integrity

002884

hsa-miR-1274bc

UCCCUGUUCGGGCGCCA

Potential normalizer (CSF)

002861

hsa-miR-1298-5pb

UUCAUUCGGCUGUCCAGAUGUA

Neural regeneration

000457

hsa-miR-132-3pb

UAACAGUCUACAGCCAUGGUCG

Vascular angiogenesis

000464

hsa-miR-142-3pb

UGUAGUGUUUCCUACUUUAUGGA

Inflammatory and immune response

002248

hsa-miR-142-5p

CAUAAAGUAGAAAGCACUACU

Inflammatory and immune response

002676

hsa-miR-144-3pb

UACAGUAUAGAUGAUGUACU

Proliferation/apoptosis/oxidative stress
Inflammatory and immune response

000468

hsa-miR-146a-5pb

UGAGAACUGAAUUCCAUGGGUU

001097

hsa-miR-146b-5p

UGAGAACUGAAUUCCAUAGGCU

Inflammatory and immune response

000473

hsa-miR-150-5p

UCUCCCAACCCUUGUACCAGUG

Inflammatory and immune response/BBB permeability

001191

hsa-miR-153-3pb

UUGCAUAGUCACAAAAGUGAUC

Neurogenesis

002623

hsa-miR-155-5pb

UUAAUGCUAAUCGUGAUAGGGGU

Inflammatory and immune response/arteriogenesis

000389

hsa-miR-15a-5pb

UAGCAGCACAUAAUGGUUUGUG

Vascular angiogenesis

000390

hsa-miR-15b-5pb

UAGCAGCACAUCAUGGUUUACA

Apoptosis/inflammatory response

000391

hsa-miR-16-5pb

UAGCAGCACGUAAAUAUUGGCG

Vascular angiogenesis

002308

hsa-miR-17-5pb

CAAAGUGCUUACAGUGCAGGUAG

Neovascularization/apoptosis/proliferation

000480

hsa-miR-181a-5pb

AACAUUCAACGCUGUCGGUGAGU

Apoptosis/inflammatory response

000482

hsa-miR-181c-5pb

AACAUUCAACCUGUCGGUGAGU

Apoptosis/inflammatory response

000494

hsa-miR-195-5pb

UAGCAGCACAGAAAUAUUGGC

Homeostasis of vessel smooth muscle cells

000396

hsa-miR-19b-3pb

UGUGCAAAUCCAUGCAAAACUGA

Neovascularization/apoptosis/proliferation

000508

hsa-miR-204-5pb,c

UUCCCUUUGUCAUCCUAUGCCU

Apoptosis/proliferation

000580

hsa-miR-20a-5pb

UAAAGUGCUUAUAGUGCAGGUAG

Neovascularization/apoptosis/proliferation

000397

hsa-miR-21-5pb

UAGCUUAUCAGACUGAUGUUGA

Apoptosis/inflammatory

000524

hsa-miR-221-3pb

AGCUACAUUGUCUGCUGGGUUUC

Apoptosis/inflammatory

002295

hsa-miR-223-3pb

UGUCAGUUUGUCAAAUACCCCA

Inflammatory and immune response

000399

hsa-miR-23a-3p

AUCACAUUGCCAGGGAUUUCC

Mitochondrial function/apoptosis

000400

hsa-miR-23b-3pb

AUCACAUUGCCAGGGAUUACC

Mitochondrial function/apoptosis

000402

hsa-miR-24-3pb

UGGCUCAGUUCAGCAGGAACAG

Apoptosis/proliferation

000408

hsa-miR-27a-3pb

UUCACAGUGGCUAAGUUCCGC

Autophagy/apoptosis

000409

hsa-miR-27b-3pb

UUCACAGUGGCUAAGUUCUGC

Autophagy/apoptosis

002112

hsa-miR-29a-3pb

UAGCACCAUCUGAAAUCGGUUA

Apoptosis/proliferation/immune response

000413

hsa-miR-29b-3pb

UAGCACCAUUUGAAAUCAGUGUU

Apoptosis/proliferation/immune response

000587

hsa-miR-29c-3pb

UAGCACCAUUUGAAAUCGGUUA

Apoptosis/proliferation/immune response

000426

hsa-miR-34a-5pb

UGGCAGUGUCUUAGCUGGUUGU

Autophagy/inflammatory response

002102

hsa-miR-34b-3pb

CAAUCACUAACUCCACUGCCAU

Autophagy/inflammatory response

001043

hsa-miR-497-5p

CAGCAGCACACUGUGGUUUGU

Apoptosis/inflammatory response

002268

hsa-miR-874-3p

CUGCCCUGGCCCGAGGGACCGA

Apoptosis/inflammatory response

000583

hsa-miR-9-5pb

UCUUUGGUUAUCUAGCUGUAUGA

Neurogenesis and differentiation

000430

hsa-miR-92a-3pb

UAUUGCACUUGUCCCGGCCUG

Neovascularization/apoptosis/proliferation
Neurogenesis, differentiation, and inflammatory response

001182

hsa-miR-124-3pb

UAAGGCACGCGGUGAAUGCC

002571

mmu-miR-155-5pd

UUAAUGCUAAUUGUGAUAGGGGU

001141

hsa-miR-451ab

AAACCGUUACCAUUACUGAGUU

Apoptosis/inflammatory response/RBC enriched

a All

selected miRNAs are known to be associated with CNS injuries or cerebral vasculature damage.
has been implicated in biomarker studies related to CNS (TBI or SCI) or stroke.
c miRNA is a potential normalizer for CSF.
d mmu-miR-155-5p was included for a separate unrelated rodent study.
b miRNA

miR-24-3p, and miR-29a-3p reached 1 (AUC = 1), signifying
a perfect discrimination between DCV+ and DCV- at a time
point prior to DCV onset. Similarly, several plasma miRNAs
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achieved AUCs greater than 0.8 (Figure 5B), demonstrating
a robust ability of selected miRNA for discriminating DCV
in two biofluids.
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FIGURE 2 | Heatmaps of overall miRNA expression in CSF and plasma specimens collected from aSAH patients and healthy controls (HC). Normalized –1CRT was
used to generate the mean expression for each miRNA in each group.

predicted 100% of the training dataset (Group A, Figure 6), and
87% of the test dataset (Group B + Group C, Table 4).

High AUC values were also achieved when comparing aSAH
and HC using CSF/PBD3 data (Supplementary Figure 3),
indicating that selected CSF miRNAs can also discriminate aSAH
patients from HCs.

Overall Prediction of the miRNA Panel
Table 4 presents a consensus prediction table incorporating 7
miRNAs with a perfect AUC of 1 and additional 19 miRNAs from
the DT. The prediction of each testing subject was determined
when at least five of the eight criteria were met for either
DCV+ or DCV-. Notably, the majority of the predictions were
uniformly accurate across the test dataset with exceptions in
only two out of 15 test cases. Case 4 had only false positive
predictions, while case 15 resulted in 5 out of 8 false positive
predictions. Despite the two false positive predictions, the overall
performance of the custom panel in predicting DCV risk
was 87% accurate.

Prediction Accuracy of the Custom
miRNA Panel on Group B and Group C
The CSF/PBD3 data from Group A was then used to build a
predicting model, and the datasets from the remaining 15 cases
from Group B (including 2 replicates from Group A) and Group
C were used for retrospective risk prediction. A risk prediction
accuracy of 93% was achieved with miR-19b-3p and miR-29a3p using the corresponding cutoff values of -0.481 and 0.53,
respectively (Table 4 and Supplementary File 1). In contrast,
miR-24-3p had only 73% accuracy using the corresponding cutoff
value of -0.011.

DISCUSSION

Decision Tree (DT) Results
MiRNAs with an AUC less than 1 were used to generate a
decision tree model (Figure 6). Out of the 19 miRNAs entered
into the model, miR-142-3p and miR-1274b were identified as
key variables in the prediction process. This model correctly

Frontiers in Molecular Biosciences | www.frontiersin.org

The potential of miRNAs serving as biomarkers for aSAH
complications was recently explored in several reports (Su et al.,
2015; Powers et al., 2016; Bache et al., 2017; Kikkawa et al.,
2017; Lu et al., 2017; Stylli et al., 2017; Lopes et al., 2018;
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TABLE 3 | Significant differential expression levels of brain and vasculature injury related miRNAs.

miRNA

CSF
III

I

II

let-7a-5p

**

ns

*

ns

ns

ns

let-7b-5p

***

ns

****

***

****

***

let-7c-5p

**

ns

**

ns

*

*

miR-103a-3p

*

ns

miR-1274b

V

VI

UD in heathy controls

miR-107
miR-125b-5p

IV

Plasma

ns

**

ns

**

II

III

IV

V

VI

**

**

ns

****

ns

***

ns

ns

ns

*

ns

ns

ns

ns

ns

*

ns

ns
**

ns

ns

ns

****

ns

***

*

***

ns

ns

*

**

ns

ns

ns

ns

ns

ns

**

ns

**

ns

**

ns
ns

UD
**

I

*

ns

*

ns

**

**

ns

ns

ns

ns

**

ns

miR-132-3p

**

ns

**

**

***

**

*

ns

ns

**

ns

miR-142-3p

***

ns

****

***

***

****

**

*

ns

***

ns

*

miR-142-5p

***

ns

*

ns

ns

**

ns

ns

miR-146a-5p

***

ns

****

***

****

***

**

ns

ns

****

ns

*

miR-146b-5p

**

ns

***

***

***

***

*

ns

ns

****

ns

**

miR-150-5p

**

ns

****

**

*

*

ns

ns

ns

**

ns

ns
***

miR-1298-5p

UD in heathy controls

miR-144-3p

UD

miR-153-3p
miR-155-5p

UD

UD

UD
ns

ns

ns

miR-15a-5p

ns

UD
ns

ns

UD

**

*

ns

****

ns

**

ns

ns

**

ns

*

miR-15b-5p

****

ns

***

*

**

*

*

ns

ns

***

ns

**

miR-16-5p

***

ns

****

***

**

**

ns

ns

ns

ns

ns

ns

miR-17-5p

***

ns

****

***

**

**

*

ns

ns

*

ns

ns

miR-181a-5p

***

ns

*

ns

*

ns

**

ns

ns

***

ns

**

miR-181c-5p

ns

ns

ns

ns

ns

ns

**

ns

ns

***

ns

*

miR-195-5p

***

ns

****

**

***

**

ns

ns

ns

ns

ns

ns

miR-19b-3p

****

ns

****

****

****

****

*

ns

ns

ns

ns

ns

miR-204-5p,

**

ns

****

*

*

ns

***

*

ns

****

ns

ns

miR-20a-5p

****

ns

****

***

****

***

*

ns

ns

*

ns

ns

miR-21-5p

**

ns

****

****

****

****

**

ns

ns

*

ns

ns

miR-221-3p

**

ns

**

*

***

***

**

*

ns

****

ns

**

miR-223-3p

***

ns

****

****

****

****

**

ns

ns

****

ns

ns

miR-23a-3p

**

ns

***

**

***

***

**

*

ns

****

ns

*

miR-23b-3p

*

ns

ns

ns

ns

ns

**

*

ns

***

ns

*

miR-24-3p

***

ns

****

***

***

***

**

ns

ns

***

ns

*

miR-27a-3p

***

ns

****

*

**

****

**

ns

ns

***

ns

*

miR-27b-3p

***

ns

**

ns

ns

*

*

ns

ns

***

ns

*

miR-29a-3p

**

ns

***

****

****

***

**

ns

ns

**

ns

ns

*

ns

ns

ns

ns
ns

miR-29b-3p

UD

miR-29c-3p

**

ns

**

*

***

**

*

ns

ns

ns

ns

miR-34a-5p

**

ns

***

***

****

****

*

ns

*

ns

*

*

miR-34b-3p

**

ns

***

ns

ns

ns

ns

ns

**

ns

**

ns

miR-497-5p

***

ns

**

ns

**

**

****

ns

*

**

ns

ns

ns

ns

ns

ns

ns

ns

miR-874-3p
miR-9-5p

UD

UD

*

ns

ns

ns

ns

ns

miR-92a-3p

***

ns

****

****

****

****

nsmiR-124-3p

**

ns

**

*

**

*

miR-451a

***

ns

*

ns

ns

ns

UD
ns

ns
UD

ns

ns

ns

Custom brain and vasculature injury miRNA panel TLDA was used to analyze CSF and plasma specimens from Group A patients (8× DCV+, 10× DCV-, 8× HC).
The differential expression was evaluated using Student’s t-test (2-tailed) between I: DCV+ vs. DCV-, PBD3; II: DCV+ vs. DCV-, PBD7; III: DCV+ vs. HC, PBD3; IV:
DCV- vs. HC, PBD3; V: DCV+ vs. HC, PBD7; VI: DCV- vs. HC, PBD7. Asterisk symbols for significant levels: ****p < 0.0001; ***p = 0.0001–0.001; **p = 0.001–0.01;
*p = 0.01–0.05; ns: p ≥ 0.05. UD, undetectable.

Pulcrano-Nicolas et al., 2018; Sheng et al., 2018a). These studies
confirmed that dysregulated miRNA expression is associated with
aSAH and its acute complications, which could be observed
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in extracellular fluids. However, there is no consensus in the
limited literature for targeting biofluid miRNAs as a valid
biomarkers for predicting DCV. This is due, in part, to significant
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FIGURE 3 | Individual CSF miRNAs that showed highly differential expression in DCV+, DCV-, and HC groups. The differential miRNA expression levels are
expressed as –1CRT and a two tailed Student’s t-test was used to evaluate differences between groups. Significant levels expressed as: ****p < 0.0001;
***p = 0.0001–0.001; **p = 0.001–0.01; *p = 0.01–0.05.

to be DCV positive (Table 4), and five of the eight predictors
incorrectly identified case 15 to be DCV positive. It is not entirely
clear why these two cases resulted in incorrect predictions, and it
may be related, in part, with the complex clinical conditions or
comorbidities of the individuals.
Several miRNAs in our panel were previously reported to
link to aSAH related complications. Significantly increased levels
of miR-21-5p and miR-221-3p in CSF were shown to associate
with delayed cerebral ischemia (DCI) and miR-221-3p, miR-1323p, and miR-19b-3p in CSF were associated with DCV (Bache
et al., 2017). In addition, CSF expression levels of miR-27a3p were differentially expressed between aSAH patients with or
without DCV (Stylli et al., 2017). Finally, temporal changes in
Let-7b-5p and miR-92a-3p in CSF, and miR-15a in both CSF and
plasma of DCI patients have been reported (Powers et al., 2016;
Kikkawa et al., 2017). In other studies, the levels of miR-146a5p, miR-17-5p, and miR-451a in whole blood were significantly
different in aSAH patients compared to the HCs (Lopes et al.,
2018). Su et al. (2015) reported that miR-132-3p is differentially
expressed in peripheral blood between DCI+ and DCI- patients.
Our data were generally consistent with the findings of
these prior studies. However, because the wide differences
in the patient cohorts, specimens used, sampling/analysis
time points, detection methodologies, and variations on study

variability across studies, including differences in sampling size
(4–129 cases), type of biofluid used (whole blood, CSF, serum,
plasma), collection time points (1–14 days), as well as miRNA
analysis methodologies. Several studies utilized time-consuming
and costly analytical methodologies such as next-generation
sequencing and microarray (Su et al., 2015; Kikkawa et al., 2017;
Pulcrano-Nicolas et al., 2018) that, while informative, may limit
clinical applications.
The major difference between our study and other reports
is that we employed a panel of selected miRNAs that is
highly relevant to brain and vasculature injury events. This
strategy directly targets a condition with a dedicated set of
miRNAs involving related pathological processes. By doing so,
the likelihood of identifying responsive biomarkers is much
greater and may be achieved using a smaller patient cohort.
Furthermore, multiple miRNAs can be used concomitantly in the
overall assessment of DCV risk to increase prediction accuracy.
Our study revealed a robust differential expression of the
selected miRNAs between DCV+ and DCV- patients, as well
as between aSAH and HCs in both CSF and plasma, with the
CSF samples showing the most pronounced difference. This
differential pattern resulted in a high prediction accuracy of
87% in our independent cohort studies. It is important to point
out that all of the predictor miRNAs falsely identified case 4

Frontiers in Molecular Biosciences | www.frontiersin.org

8

May 2021 | Volume 8 | Article 657258

Wang et al.

miRNA Panel Determines DCV Risk

FIGURE 4 | Individual plasma miRNAs that showed highly differential expression in DCV+, DCV–, and HC groups. The differential miRNA expression levels are
expressed as –1CRT and a two tailed Student’s t-test was used to evaluate the difference between groups. Significant levels expressed as: ****p < 0.0001;
***p = 0.0001–0.001; **p = 0.001–0.01; *p = 0.01–0.05.

FIGURE 5 | ROC analysis of miRNAs using Group A CSF and plasma data collected at PBD3 from aSAH patients. ROC curve constructed using (A) DCV+ and
DCV– groups of CSF miRNA data; (B) DCV+ and DCV– groups of plasma miRNA data.
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TABLE 4 | Overall performance of DCV risk prediction of the custom miRNA panel.
Test case

Let-7b-5p

miR-15b-5p

miR-17-5p

miR-19b-3p

miR-20a-5p

miR-24-3p

Vote

Observation

1

Yes (X)

Yes (X)

Yes (X)

Yes (X)

Yes(X)

No (×)

miR-29a-3p Decision tree
Yes (X)

Yes (X)

Yes

Yes

2

No (X)

No (X)

No (X)

No (X)

No (X)

No (X)

No (X)

No (X)

No

No

3

Yes (X)

Yes (X)

Yes (X)

Yes (X)

Yes (X)

Yes (X)

Yes (X)

Yes (X)

Yes

Yes

4

Yes (×)

Yes (×)

Yes (×)

Yes (×)

Yes (×)

Yes (×)

Yes (×)

Yes (×)

Yes

No

5

Yes (X)

Yes (X)

Yes (X)

Yes (X)

Yes (X)

Yes (X)

Yes (X)

Yes (X)

Yes

Yes

6

Yes (×)

No (X)

No (X)

No (X)

No (X)

No (X)

No (X)

No (X)

No

No

7

Yes (X)

Yes (X)

Yes (X)

Yes (X)

Yes (X)

No (×)

Yes (X)

Yes (X)

Yes

Yes

8

No (X)

No (X)

No (X)

No (X)

No (X)

No (X)

No (X)

No (X)

No

No

9

Yes (X)

Yes (X)

Yes (X)

Yes (X)

Yes (X)

Yes (X)

Yes (X)

Yes (X)

Yes

Yes
No

10

No (X)

No (X)

No (X)

No (X)

No (X)

Yes (×)

No (X)

No (X)

No

11

No (X)

No (X)

No (X)

No (X)

No (X)

No (X)

No (X)

No (X)

No

No

12

Yes (X)

Yes (X)

Yes (X)

Yes (X)

Yes (X)

Yes (X)

Yes (X)

Yes (X)

Yes

Yes
Yes

13

Yes (X)

Yes (X)

Yes (X)

Yes (X)

Yes (X)

Yes (X)

Yes (X)

Yes (X)

Yes

14

No (X)

Yes (×)

No (X)

No (X)

No (X)

Yes (×)

No (X)

No (X)

No

No

15

Yes (×)

Yes (×)

Yes (×)

No (X)

Yes (×)

No (X)

No (X)

Yes (×)

Yes

No

Cutoff

0.248

−0.038

−0.603

−0.481

−0.925

−0.011

0.530

12

12

13

14

13

11

14

13

13

0.80

0.80

0.87

0.93

0.87

0.73

0.93

0.87

0.87

Correct predictions
Accuracy

Observed values

Predicted values

Yes

No

Yes

True positive

False positive

No

False negative

True negative

The table includes seven highly predictive individual miRNAs and the prediction using the decision tree. The cutoff values for each individual miRNA predictor were
the mean of the values from the DCV+ and DCV- cases. The cutoff value calculations and corresponding specificity and sensitivity in this prediction can be found in
Supplementary File 1.

focus (e.g., aSAH vs. control, occurrence of DCV or DCI, etc.),
it is difficult to make direct comparisons between our results and
those reported in the previously published studies.

Another important advantage of our panel is that individual
miRNAs are easily replaced if they do not perform well. Not all of
the miRNAs on our current panel contributed to DCV prediction
and several miRNAs were excluded from further analysis due to
their low expression levels (e.g., miR-144-5p, miR-153-3p, and
miR-874-3p). In addition, other miRNAs, such as miR-1298-5p
in CSF and miR-16-5p in plasma, did not differentiate between
DCV+ and DCV-. Therefore, replacing these miRNAs with other
candidate miRNAs, for example, miR-502, miR-516a-5p, and
miR-1297 (Lai et al., 2017; Stylli et al., 2017), that may prove more
effective in DCV prediction will be considered in future studies.
We recognize that there are several limitations with our
current study. First, the patient cohort was relatively small, and
samples were limited to two institutions. This can be partially
attributed to the rarity of aSAH. The incidence of aSAH is 6–
16 cases per 100,000 persons, with approximately 30,000 cases
occurring each year in the United States (de Rooij et al., 2007).
To fully address this limitation and to validate the DCV miRNA
panel, future studies will need to expand the patient cohort
and include recruitment from various medical institutions. In
addition, we are currently exploring the possibility of validating
our data in aSAH animal models. Second, there were only two
sampling time points. Prior studies reported that altered miRNA
expression levels in biofluids following aSAH are temporally
dynamic (Powers et al., 2016; Kikkawa et al., 2017; Sheng et al.,
2018b; Bache et al., 2020). Therefore, it will be critical to identify
a time point that shows the greatest differences in miRNA
expression levels and, more importantly, provides the earliest
prediction to allow clinicians time to make medical decisions.

FIGURE 6 | Decision tree prediction model was generated using the Group A
training dataset. Out of the 19 variables entered into the model, miR-142-3p
and miR-1274b were identified as key variables in the prediction process.
Specifically, these two miRNAs correctly predicted 100% of the Group A
training dataset.
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procurement. WXW, KWH, JES, KX, and DWF: manuscript
editing and review. All authors contributed to the article and
approved the submitted version.

Third, the detection of DCV miRNAs was solely based on
TaqMan miRNA assay technology. Although this technology has
also been successfully applied in other aSAH miRNA studies
(Bache et al., 2017, 2020), it will be important to validate
this miRNA panel using a different detection method to avoid
technological bias. Lastly, the current study did not correlate the
expression of selected miRNAs with other aSAH complications,
such as DCI or early brain injury, nor with the prognosis. Our
focus was to examine DCV after aSAH and future studies are
warranted to evaluate how this novel miRNA biomarker panel
might be applied these other scenarios and how it might impact
clinical practice.
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